Vanderbilt: Early Research Shows Promise for Therapeutics That Delay Type 2 Diabetes
January 13, 2021
January 13, 2021
NASHVILLE, Tennessee, Jan. 13 (TNSJou) -- Vanderbilt University issued the following news:
Vanderbilt researchers have discovered a unique pathway that initiates islet Beta cell inflammation--a hallmark of type 2 diabetes--putting them a step closer to developing targeted therapeutics for the disease that affects one in 10 Americans.
The article, "RIPK3-mediated inflammation is a conserved Beta-cell response to ER stress" was published in the journal Science A . . .
Vanderbilt researchers have discovered a unique pathway that initiates islet Beta cell inflammation--a hallmark of type 2 diabetes--putting them a step closer to developing targeted therapeutics for the disease that affects one in 10 Americans.
The article, "RIPK3-mediated inflammation is a conserved Beta-cell response to ER stress" was published in the journal Science A . . .